Nanomedicine and theranostics
רחלה פופובצר
Identity: verifiedThe BIU profile uses the source-spelled name Rachela Popovtzer and matches the roster. [53]
Documented foundation
Popovtzer develops smart nanoprobes that combine molecular imaging and targeted therapy concepts across chemistry, engineering, biology, and radiology.[53]
gold nanoparticlesmolecular imagingtargeted drug deliverynano-bioengineering
The institutional profile and laboratory publication record were inspected; no standalone CV was verified.[53]
Representative records, not a complete publication list. Metadata confirms attribution; it does not independently replicate a result.
2017 · paper
Reports an imaging-oriented gold-nanoparticle approach for stratifying anti-PD-L1 immunotherapy in the studied setting.[54]
8 catalogued patent records · 7 identified families · family unassigned for 1 record
Coverage: Partial inventor search
Seven additional family representatives located across Bar-Ilan, Nanocarry, Ariel and Ramot/Tel-Aviv contexts. The retained US12569569B2 already represents the original nano-delivery family. Exact name, nanomedicine/electrochemical subject and co-inventor continuity support attribution; current ownership and clinical effects are not established.
US20260091125A1 · Published 2026-04-02
Published patent document inspected
Publication assignee: Nanocarry Therapeutics Ltd
Named inventor Rachela Popovtzer; exact uncommon name, matching technical area and co-inventor continuity with baseline nanomedicine research; independent review pending. Assignee is the captured publication metadata, not a current-ownership determination.[240]
US12226496B2 · Published 2025-02-18
Published patent document inspected
Publication assignee: Bar Ilan University
Named inventor Rachela Popovtzer; exact uncommon name, matching technical area and co-inventor continuity with baseline nanomedicine research; independent review pending. Assignee is the captured publication metadata, not a current-ownership determination.[241]
US20240345080A1 · Published 2024-10-17
Published patent document inspected
Publication assignee: Bar Ilan University
Named inventor Rachela Popovtzer; exact uncommon name, matching technical area and co-inventor continuity with baseline nanomedicine research; independent review pending. Assignee is the captured publication metadata, not a current-ownership determination.[242]
US20240293561A1 · Published 2024-09-05
Published patent document inspected
Publication assignee: Nanocarry Therapeutics Ltd
Named inventor Rachela Popovtzer; exact uncommon name, matching technical area and co-inventor continuity with baseline nanomedicine research; independent review pending. Assignee is the captured publication metadata, not a current-ownership determination.[243]
US10478132B2 · Published 2019-11-19
Published patent document inspected
Publication assignee: Bar Ilan University
Named inventor Rachela Popovtzer; exact uncommon name, matching technical area and co-inventor continuity with baseline nanomedicine research; independent review pending. Assignee is the captured publication metadata, not a current-ownership determination.[244]
US10421785B2 · Published 2019-09-24
Published patent document inspected
Publication assignee: Bar Ilan University; Ariel Scientific Innovations Ltd
Named inventor Rachela Popovtzer; exact uncommon name, matching technical area and co-inventor continuity with baseline nanomedicine research; independent review pending. Assignee is the captured publication metadata, not a current-ownership determination.[245]
US8268577B2 · Published 2012-09-18
Published patent document inspected
Publication assignee: Ramot at Tel Aviv University Ltd
Named inventor Rachela Popovtzer; exact uncommon name, matching technical area and co-inventor continuity with baseline nanomedicine research; independent review pending. Assignee is the captured publication metadata, not a current-ownership determination.[246]
US12569569B2
Original report record
Preserved from the original report; see its cited evidence and limitations.[55]
Original evidence: verified record
A Google Patents record verifies inventor attribution; current legal ownership and clinical efficacy are not inferred. The original research pass inspected the linked record, but an independent reviewer could not reopen it after bounded retries; record-specific independent review remains incomplete.[55]
Records are counted separately from identified families. Author-reported entries are labelled and may still need publication verification. Inventorship, publication-time applicant and current ownership are different facts. No legal-status, patentability or freedom-to-operate conclusion is made.
Scores prioritize research fit from 1–10; they are not probabilities.
Review: Reviewed with limitations
Proposed capability matches, not confirmed relationships. Scores are analyst judgments with low forecast confidence; researcher interests, capacity and feasibility need confirmation.
10 candidates
Connection 1
Original proposal
Proposal hypothesis: Danielli's magnetic-optical assays and Popovtzer's nanoparticle functionalization meet on specific binding versus sample-background interference.[45][46][47][53][54]
Proposed first test: Compare a reference bead assay with one candidate functionalization in a blinded dilution and interference panel; measure recovery and nonspecific signal.
Rank 1/10; fit 9/10 (4 topic overlap + 3 complementarity + 2 feasible first test). Preserved original co-membership proposal in o06. No strictly higher-scoring candidate displaces this original. No compatibility between gold probes and the selected magnetic assay is assumed before bench qualification. No automatic score boost for original membership. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work.
Connection 2
Proposal hypothesis: Shefi's regenerative neural interfaces and Popovtzer's targeted nanoprobes can separate cell organization from nanoparticle uptake.[8][53][54]
Proposed first test: Specify a neural-culture panel with matched particle exposure and geometry controls; compare uptake, viability and neurite alignment.
Rank 2/10; fit 9/10 (4 topic overlap + 3 complementarity + 2 feasible first test). New pairing outside the frozen portfolio co-member graph. Targeted delivery and regenerative benefit are not assumed; particle and culture compatibility must be established. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work.
Connection 3
Original proposal
Proposal hypothesis: Popovtzer can define nanoprobe contrast and nonspecific uptake controls while Zalevsky assesses an optical imaging readout.[53][54][116][117][138]
Proposed first test: Use a tissue-mimicking phantom with known probe concentrations to compare contrast recovery and depth sensitivity against a conventional image.
Rank 3/10; fit 8/10 (3 topic overlap + 3 complementarity + 2 feasible first test). Preserved original co-membership proposal in o06. An added candidate, Orit Shefi (9/10), ranks above this original because its stated pair-specific roles and first test score higher; this original is limited as follows: An optical phantom cannot establish in-vivo targeting, safety or therapeutic efficacy. No automatic score boost for original membership. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work. Original initiative conditions remain: o06 Zeev Zalevsky: Conditional later role: assess an imaging/readout change only if it targets the dominant measured bottleneck.
Connection 4
Proposal hypothesis: Tesler's surface chemistry and Popovtzer's targeted nanoprobes meet on unintended protein adsorption versus retained targeting.[12][13][53][54]
Proposed first test: Specify a small coating/probe panel and compare nonspecific protein binding with target-binding retention in an acellular assay.
Rank 4/10; fit 8/10 (3 topic overlap + 3 complementarity + 2 feasible first test). New pairing outside the frozen portfolio co-member graph. Surface treatments may suppress both unwanted and desired binding. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work.
Connection 5
Proposal hypothesis: Popovtzer's imaging probes and Alon's spatial transcriptomics could examine whether probe localization corresponds to molecular tissue state.[53][54][60][61]
Proposed first test: Compare a candidate imaging marker with a public spatial-expression atlas, then define a co-registration control for a future matched specimen.
Rank 5/10; fit 8/10 (3 topic overlap + 3 complementarity + 2 feasible first test). New pairing outside the frozen portfolio co-member graph. Expression is only a proxy for probe binding; no matched specimen access is confirmed. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work.
Connection 6
Proposal hypothesis: Popovtzer can define nanoparticle targeting controls while Kalisky distinguishes cellular states that may explain heterogeneous uptake.[53][54][70]
Proposed first test: Use a public cell-state dataset to preregister target-positive and target-negative groups for a later blinded uptake assay.
Rank 6/10; fit 8/10 (3 topic overlap + 3 complementarity + 2 feasible first test). New pairing outside the frozen portfolio co-member graph. RNA-defined states do not establish accessible protein targets or therapeutic response. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work.
Connection 7
Original proposal
Proposal hypothesis: Popovtzer's imaging nanoprobes and Lewi's light-matter design could test whether a spectral surface improves probe discrimination in complex backgrounds.[53][54][67][68]
Proposed first test: Model measured or openly reported probe spectra through a candidate metasurface response and compare separation with ordinary bandpass filtering.
Rank 7/10; fit 7/10 (2 topic overlap + 3 complementarity + 2 feasible first test). Preserved original co-membership proposal in o06. An added candidate, Orit Shefi (9/10), ranks above this original because its stated pair-specific roles and first test score higher; this original is limited as follows: Probe-surface compatibility and a relevant optical bottleneck need confirmation before fabrication or biological testing. No automatic score boost for original membership. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work. Original initiative conditions remain: o06 Tomer Lewi: Conditional later role: add a photonic component only if the baseline study identifies an optical bottleneck that it can address.
Connection 8
Proposal hypothesis: Levy's biological-network models could test whether heterogeneity relevant to Popovtzer's targeting probes follows cell-state networks rather than mean marker levels.[5][6][53][54]
Proposed first test: On an open single-cell dataset, compare target-marker neighbourhood structure with a composition-only model under held-out samples.
Rank 8/10; fit 7/10 (2 topic overlap + 3 complementarity + 2 feasible first test). New pairing outside the frozen portfolio co-member graph. This generates targeting hypotheses only; uptake, biodistribution and efficacy require separate experiments. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work.
Connection 9
Proposal hypothesis: Panfil's emissive nanocrystals and Popovtzer's molecular-imaging probes could compare optical-label stability under the same acellular background conditions.[25][26][53][54]
Proposed first test: Define a blinded brightness and nonspecific-binding panel comparing a candidate nanocrystal label with a reference nanoprobe.
Rank 9/10; fit 7/10 (2 topic overlap + 3 complementarity + 2 feasible first test). New pairing outside the frozen portfolio co-member graph. Quantum-emitter behaviour, targeting and biological safety cannot be transferred across particle chemistries. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work.
Connection 10
Proposal hypothesis: Popovtzer's nanoprobe material questions could be narrowed into a surface-response model for Goldzak Mizrahi's electronic-structure methods.[53][54][132][133]
Proposed first test: For one small documented probe-surface model, compare binding or optical-response trends across two terminations against published measurements.
Rank 10/10; fit 7/10 (2 topic overlap + 3 complementarity + 2 feasible first test). New pairing outside the frozen portfolio co-member graph. A tractable microscopic model may not represent a complete functionalized nanoparticle in biological media. Equal scores use existing-first, then stable researcher ID.
Analyst proposal hypothesis, not an established collaboration, commitment, evidence-confidence rating or assessment of researcher quality; confirm participation and access before work.
10 candidates
Connection 1
Massachusetts Institute of Technology
Original proposal
Her layer-by-layer nanoparticle delivery expertise could complement Popovtzer’s imaging and targeting program; no willingness or existing collaboration is asserted.[53][56][460]
Compare a single-layer probe with a two-stage formulation in an organoid model using predefined uptake and release endpoints.
Rank 1/10 after semantic revision; analyst score 9 = max(1, 4+3+2): topic overlap 4/4, complementarity 3/3, feasible first test 2/3. The experiment, numerical inputs or identity/scope needs confirmation before execution. Original remains first under these components; original status breaks equal-score ties only, without a prestige bonus.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified. The official page has differing leadership titles in its header and biography; only MIT affiliation is asserted.
Connection 2
Massachusetts Institute of Technology
Proposed capability match: Rachela Popovtzer's gold nanoparticles, molecular imaging can be paired with Robert S. Langer's documented controlled drug delivery, polymer and lipid materials for programmable staged theranostic nanoparticles. The specific contribution is controlled release and formulation stability; this transfer is an analyst hypothesis.[53][466]
Compare two carrier formulations at equal loading through a release-and-stability time course using a planned targeted nanoparticle/spheroid or barrier-model study with matched payload dose. Compare release profile, active-payload retention and batch variability with a single-stage carrier with the same targeting ligand and total loading.
Rank 2/10 after semantic revision; analyst score 9 = max(1, 4+3+2): topic overlap 4/4, complementarity 3/3, feasible first test 2/3. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified.
Connection 3
Harvard University
Proposed capability match: Rachela Popovtzer's gold nanoparticles, molecular imaging can be paired with Samir Mitragotri's documented drug delivery, biological barriers for programmable staged theranostic nanoparticles. The specific contribution is transport across biological barriers; this transfer is an analyst hypothesis.[53][477]
Compare carrier-associated and free-payload transport in a defined barrier model with matched dose using a planned targeted nanoparticle/spheroid or barrier-model study with matched payload dose. Compare transfer efficiency, retained activity and nonspecific uptake with a single-stage carrier with the same targeting ligand and total loading.
Rank 3/10 after semantic revision; analyst score 9 = max(1, 4+3+2): topic overlap 4/4, complementarity 3/3, feasible first test 2/3. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified.
Connection 4
Harvard University
Proposed capability match: Rachela Popovtzer's gold nanoparticles, molecular imaging can be paired with Donald E. Ingber's documented organ chips, mechanobiology for programmable staged theranostic nanoparticles. The specific contribution is flow and tissue interfaces under controlled conditions; this transfer is an analyst hypothesis.[53][462]
Design a microfluidic or organ-chip challenge with controlled shear and matched surface controls using a planned targeted nanoparticle/spheroid or barrier-model study with matched payload dose. Compare flow-dependent adhesion, permeability and toxicity proxies with a single-stage carrier with the same targeting ligand and total loading.
Rank 4/10 after semantic revision; analyst score 8 = max(1, 3+3+2): topic overlap 3/4, complementarity 3/3, feasible first test 2/3. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified.
Connection 5
Harvard University
Proposed capability match: Rachela Popovtzer's gold nanoparticles, molecular imaging can be paired with David J. Mooney's documented cell-responsive biomaterials, mechanobiology for programmable staged theranostic nanoparticles. The specific contribution is biochemical and mechanical cues at cell-material interfaces; this transfer is an analyst hypothesis.[53][480]
Vary one material cue while holding geometry and biochemical loading fixed in a designed culture experiment using a planned targeted nanoparticle/spheroid or barrier-model study with matched payload dose. Compare cell response, adhesion and viability with a single-stage carrier with the same targeting ligand and total loading.
Rank 5/10 after semantic revision; analyst score 8 = max(1, 3+3+2): topic overlap 3/4, complementarity 3/3, feasible first test 2/3. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified.
Connection 6
Harvard University and the Wyss Institute
Proposed capability match: Rachela Popovtzer's gold nanoparticles, molecular imaging can be paired with David Walt's documented single-molecule detection, biomarker assays for programmable staged theranostic nanoparticles. The specific contribution is single-molecule assay design and controls; this transfer is an analyst hypothesis.[49][53][501]
Construct a dilution-series protocol with blank, spike-recovery and interferent controls using a planned targeted nanoparticle/spheroid or barrier-model study with matched payload dose. Compare limit-of-blank behavior, recovery and false-positive rate with a single-stage carrier with the same targeting ligand and total loading.
Rank 6/10 after semantic revision; analyst score 8 = max(1, 3+3+2): topic overlap 3/4, complementarity 3/3, feasible first test 2/3. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified.
Connection 7
Harvard University
Proposed capability match: Rachela Popovtzer's gold nanoparticles, molecular imaging can be paired with Joanna Aizenberg's documented adaptive bioinspired surfaces, surface chemistry for programmable staged theranostic nanoparticles. The specific contribution is adaptive interfacial chemistry; this transfer is an analyst hypothesis.[15][53][431]
Contrast static and responsive surface designs under a controlled environmental perturbation using a planned targeted nanoparticle/spheroid or barrier-model study with matched payload dose. Compare surface response, reversibility and fouling or adhesion change with a single-stage carrier with the same targeting ligand and total loading.
Rank 7/10 after semantic revision; analyst score 7 = max(1, 2+3+2): topic overlap 2/4, complementarity 3/3, feasible first test 2/3. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified.
Connection 8
Harvard University
Proposed capability match for Rachela Popovtzer with Jennifer A. Lewis: Printing could provide a controlled assay geometry for nanoparticle delivery; it must be compared through the same transport/exposure endpoint, not against a different carrier.[53][468]
Simulate transport through two printable porous assay-chamber geometries with identical carrier formulation, payload dose and inlet conditions. Compare predicted nanoparticle exposure at a model spheroid surface and flow resistance; hold uptake kinetics fixed and report sensitivity to pore-size tolerances. Geometry feasibility precedes biological uptake claims.
Rank 8/10 after semantic revision; analyst score 7 = max(1, 2+3+2): topic overlap 2/4, complementarity 3/3, feasible first test 2/3. Printing could provide a controlled assay geometry for nanoparticle delivery; it must be compared through the same transport/exposure endpoint, not against a different carrier. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified. Post-review scope: Printing could provide a controlled assay geometry for nanoparticle delivery; it must be compared through the same transport/exposure endpoint, not against a different carrier. This revised proposal awaits independent targeted re-review; simulated outcomes would establish model behavior only, not biological, clinical or deployed benefit.
Connection 9
Stanford University
Proposed capability match for Rachela Popovtzer with Stephen Quake: Single-cell isolation expertise could reveal uptake-measurement bias; capture performance is useful only through an explicit common delivery/uptake endpoint.[53][487]
Generate synthetic per-cell nanoparticle uptake values and a sampling model with capture bias, doublets and cell loss. Compare two isolation/sampling assumptions using the same underlying cell population and dose; report error in estimated mean uptake and rare high-uptake fraction. Physical isolation and any spheroid study remain later validated stages.
Rank 9/10 after semantic revision; analyst score 7 = max(1, 2+3+2): topic overlap 2/4, complementarity 3/3, feasible first test 2/3. Single-cell isolation expertise could reveal uptake-measurement bias; capture performance is useful only through an explicit common delivery/uptake endpoint. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified. Post-review scope: Single-cell isolation expertise could reveal uptake-measurement bias; capture performance is useful only through an explicit common delivery/uptake endpoint. This revised proposal awaits independent targeted re-review; simulated outcomes would establish model behavior only, not biological, clinical or deployed benefit.
Connection 10
University of Florida
Proposed capability match for Rachela Popovtzer with Christine Schmidt: Schmidt's neural biomaterial expertise motivates only a conditional neural-delivery branch; generic tumour spheroids do not justify neurite-growth endpoints or neural application.[11][53][493]
First confirm whether a neural-delivery application is intended. If so, model diffusion of the same nanoparticle payload through two neural-scaffold material surrogates with identical geometry and loading, comparing predicted release and exposure against a no-scaffold transport control. Neurite extension and neural efficacy require a separately justified cell model and new experiments.
Rank 10/10 after semantic revision; analyst score 4 = max(1, 1+2+1): topic overlap 1/4, complementarity 2/3, feasible first test 1/3. Schmidt's neural biomaterial expertise motivates only a conditional neural-delivery branch; generic tumour spheroids do not justify neurite-growth endpoints or neural application. The experiment, numerical inputs or identity/scope needs confirmation before execution.
Proposed fit, not an assertion of a new or active relationship. Independent review pending; forecast confidence low. Partner interest, capacity, data access and any required experimental approvals/resources are unverified. Natural biomaterial compatibility is the contribution; the inspected evidence establishes neural regeneration, not cancer-specific nanoparticle expertise. Post-review scope: Schmidt's neural biomaterial expertise motivates only a conditional neural-delivery branch; generic tumour spheroids do not justify neurite-growth endpoints or neural application. This revised proposal awaits independent targeted re-review; simulated outcomes would establish model behavior only, not biological, clinical or deployed benefit.
Rachela Popovtzer has source-grounded capabilities in nanomedicine and theranostics, represented here by gold nanoparticles, molecular imaging, targeted drug delivery. [53][54]
Moderate confidenceReview: reviewedThe sources establish public professional activity, not comparative quality, future performance, or willingness to participate.
Hypothesis for 2027–2031: Rachela Popovtzer could explore programmable staged theranostic nanoparticles through the bounded first test described in this profile. [53][54][56]
Low confidenceReview: reviewedBiocompatibility, manufacturability, and added value over simpler particles require testing.
